Choosing the best first-line therapy for extensive-stage small-cell lung cancer: anti-PD-1 or anti-PD-L1 inhibitors?

ABSTRACT:

Background

This study addresses the lack of a comprehensive meta-analysis comparing the efficacy and safety of first-line anti-blocking the programmed cell death 1 (PD-1) and anti-programmed death ligand 1 (PD-L1) therapies in patients with extensive-stage small-cell lung cancer, using reconstructed individual patient data.

Methods

Through systematic review, we extracted relevant studies from PubMed and EMBASE databases, spanning January 1, 2010 to November 28, 2024. Only phase III randomized controlled trials assessing anti-PD-1 inhibitors plus chemotherapy (CT) versus anti-PD-L1 inhibitors plus CT were selected. To compare survival outcomes, we employed WebPlotDigitizer and R software for survival curve reconstruction, aiming to elucidate the comparative effectiveness and

SUBMITTER: Zhu S 

PROVIDER: S-EPMC12419250 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature